Login to Your Account



For $55M, OSI Gets Novantrone U.S. Cancer Rights From Serono

By James Etheridge


Wednesday, March 19, 2003
Serono SA signed a licensing agreement with OSI Pharmaceuticals Inc., granting OSI exclusive rights to market and promote Novantrone in the U.S. in its approved oncology indications. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription